论文部分内容阅读
随着皮肤T细胞淋巴瘤(CTCL)分子生物学研究的发展,靶向治疗作为其治疗的新手段逐渐成为热点。目前多个针对CTCL的分子靶点及其靶向药物正在研究中并已经运用于临床,主要包括单克隆抗体、免疫偶联物、组蛋白脱乙酰酶抑制剂及免疫检查点抑制剂等,这些药物分别作用于不同的靶分子发挥作用。该文对CTCL常见靶向药物的发展现状及研究进展作一综述。
With the development of molecular biology of cutaneous T-cell lymphoma (CTCL), targeted therapy has become a hot spot as a new treatment method. At present, many molecular targets for CTCL and their targeted drugs are under study and have been used clinically, mainly including monoclonal antibodies, immunoconjugates, histone deacetylase inhibitors and immune checkpoint inhibitors, etc. Drugs act on different target molecules, respectively. This article reviews the current status and research progress of CTCL common targeted drugs.